Mar. 9 at 8:03 PM
$TGTX No doubt Briumvi should be Rx for RMS pts. With highly active disease.
Should be used earlier too; as in frontline treatment instead of just RMS. 👍🍀💎
Key Efficacy Results
"In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction (P<0.001).
At Week 12, BRIUMVI reduced the least squares mean number of Gd+ T1 lesions by 83.3% compared with teriflunomide (0.114 vs 0.683; P<0.001). During Weeks 0–96, Gd+ T1 lesions were reduced by 95.6% with BRIUMVI versus teriflunomide (0.038 vs 0.875; P<0.001)."
https://finance.yahoo.com/news/data-published-neurology-therapy-demonstrate-113000693.html
